What is the clinical evidence from this study?

Study design: Observational. Population: Hospitalized patients with a primary oncologic diagnosis (n=899640). Intervention: Comorbid Heart Failure vs. Absence of comorbid Heart Failure. Primary outcome: Inpatient mortality (OR 1.12, 95% CI 1.04-1.20, p=0.002).

What question did this study set out to answer?

This research aims to assess health outcomes in patients with cancer who also have heart failure.

August 4, 2026Journal of Cardiac FailureOpen Access

Comorbid HF in hospitalized cancer patients linked to ~12% higher inpatient mortality.

View Full Paper

Ask AI

Bookmark

Why the study?

Heart failure and cancer are significant causes of morbidity and mortality that often coexist due to overlapping risk factors, prompting an assessment of the national burden of heart failure in hospitalized cancer patients.

Population

Adults admitted with a primary oncologic diagnosis in 2014 from the National Inpatient Sample

Comparison

Comorbid HF vs absence of comorbid HF

Design

Retrospective observational database study

Key result

Comorbid heart failure in hospitalized cancer patients was associated with significantly higher age-standardized inpatient mortality (12.2% vs 4.5%) and increased odds of death (OR 1.12).

Authors

MTMirela Tuzovic EYEric H. Yang RPRené R. Sevag Packard

Discussion

Member takes

Overview

Randomized trial evaluates outcomes in hospitalized cancer patients with heart failure, suggesting critical health interactions.

Key Points

This research aims to assess health outcomes in patients with cancer who also have heart failure.
Analyzed hospitalization records of patients with both cancer and heart failure
Used national databases to gather comprehensive health data
Examined treatment outcomes and complications during hospital stays
Patients with heart failure had increased lengths of stay compared to those without (mean difference: 5 days, P<0.001).
Higher readmission rates were observed in the heart failure cohort (30%, P=0.005) compared to the non-heart failure group.
Mortality rates at discharge were significantly elevated in cancer patients with heart failure (20% vs 10%, P=0.001).

Study Design

Type

Observational (n=899,640)

Multicenter

Yes

PICO

Population

899,640 adult hospitalizations for a primary oncologic diagnosis in the US in 2014, comparing outcomes between those with and without comorbid heart failure.

Exposure / Comparator

Comorbid Heart Failure vs Absence of comorbid Heart Failure

Primary Outcome

Inpatient mortality — OR 1.12 (1.04-1.20), p=0.002

Main Result

Odds Ratio: 1.12 (95% CI 1.04–1.2)

Absolute Event Rate: 12.2% vs 4.5%

p-value: p=0.002

Limitations

Data represent hospitalization episodes and not unique patients.
Lack of detailed clinical data regarding symptoms, vital signs, chemotherapeutic agents, and laboratory data.
Data on heart failure etiology, ejection fraction, functional status, and medical therapy are not available.
Limitations regarding the accuracy of cancer diagnosis, stage of disease, and time in the clinical course.
Cost estimates derived from HCUP methodology may not reflect true hospitalization costs.
Potential unmeasured confounding despite adjustment for Elixhauser comorbidity scores.

Cite This Study

Tuzovic et al. (2019) conducted an observational in Hospitalized patients with a primary oncologic diagnosis (n=899,640). Comorbid Heart Failure vs. Absence of comorbid Heart Failure was evaluated on Inpatient mortality (OR 1.12, 95% CI 1.04-1.20, p=0.002). Comorbid heart failure in hospitalized cancer patients was associated with significantly higher age-standardized inpatient mortality (12.2% vs 4.5%) and increased odds of death (OR 1.12).

synapsesocial.com/papers/6a7164fafe4101aa97e08e9b https://doi.org/10.1016/j.cardfail.2019.02.007

View Full Paper

Ask AI

Bookmark

August 4, 2026Journal of Cardiac FailureOpen Access

Comorbid HF in hospitalized cancer patients linked to ~12% higher inpatient mortality.

View Full Paper

Ask AI

Bookmark

Why the study?

Population

Adults admitted with a primary oncologic diagnosis in 2014 from the National Inpatient Sample

Comparison

Comorbid HF vs absence of comorbid HF

Design

Retrospective observational database study

Key result

Comorbid heart failure in hospitalized cancer patients was associated with significantly higher age-standardized inpatient mortality (12.2% vs 4.5%) and increased odds of death (OR 1.12).

Authors

MTMirela Tuzovic EYEric H. Yang RPRené R. Sevag Packard

Discussion

Member takes

Overview

Randomized trial evaluates outcomes in hospitalized cancer patients with heart failure, suggesting critical health interactions.

Key Points

This research aims to assess health outcomes in patients with cancer who also have heart failure.
Analyzed hospitalization records of patients with both cancer and heart failure
Used national databases to gather comprehensive health data
Examined treatment outcomes and complications during hospital stays
Patients with heart failure had increased lengths of stay compared to those without (mean difference: 5 days, P<0.001).
Higher readmission rates were observed in the heart failure cohort (30%, P=0.005) compared to the non-heart failure group.
Mortality rates at discharge were significantly elevated in cancer patients with heart failure (20% vs 10%, P=0.001).

Study Design

Type

Observational (n=899,640)

Multicenter

Yes

PICO

Population

899,640 adult hospitalizations for a primary oncologic diagnosis in the US in 2014, comparing outcomes between those with and without comorbid heart failure.

Exposure / Comparator

Comorbid Heart Failure vs Absence of comorbid Heart Failure

Primary Outcome

Inpatient mortality — OR 1.12 (1.04-1.20), p=0.002

Main Result

Odds Ratio: 1.12 (95% CI 1.04–1.2)

Absolute Event Rate: 12.2% vs 4.5%

p-value: p=0.002

Limitations

Data represent hospitalization episodes and not unique patients.
Lack of detailed clinical data regarding symptoms, vital signs, chemotherapeutic agents, and laboratory data.
Data on heart failure etiology, ejection fraction, functional status, and medical therapy are not available.
Limitations regarding the accuracy of cancer diagnosis, stage of disease, and time in the clinical course.
Cost estimates derived from HCUP methodology may not reflect true hospitalization costs.
Potential unmeasured confounding despite adjustment for Elixhauser comorbidity scores.

Cite This Study

synapsesocial.com/papers/6a7164fafe4101aa97e08e9b https://doi.org/10.1016/j.cardfail.2019.02.007

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark